ReviewThrombomodulin: tumour biology and prognostic implications
Introduction
Thrombomodulin (TM) was first described as an integral component of the haemostatic pathway in 1981.1 Constitutively expressed on the vascular and lymphatic endothelium, TM interacts with thrombin to form a high-affinity complex that inhibits thrombin activity (fibrin formation) and accelerates protein C activation.2, 3 In addition to this anticoagulant function, TM reduces fibrinolysis by activating thrombin-activatable fibrinolysis inhibitor (TAFI) in plasma.4 Thus, induced TM deficiency (genetic knock-out in mice) results in a hypercoagulable state with risk of arterial thrombotic disease.5
Soluble molecules of TM, released from endothelial cell surfaces, are found in plasma and urine where higher levels indicate injury and/or enhanced turnover of the endothelium.6, 7, 8 It is not surprising, therefore, that smokers display increased serum soluble TM concentrations that correlate with activated protein C levels, number of cigarettes smoked (per day), duration of smoking (years), degree of endothelial damage, and risk of thrombosis.9, 10 Serum TM elevations, by neutrophil-mediated proteolytic/oxidative cleavage or hypoxia-induced shedding from the endothelium, parallel the activity of inflammatory diseases (e.g. vasculidites and ulcerative colitis), ischaemia-reperfusion injuries (i.e. vascular, cardiac, and transplant surgery), and atherosclerotic complications (e.g. in hypertension, smoking, and diabetes).11, 12, 13, 14, 15, 16 Clinical use of exogenous soluble infusions is approaching with recent report that administration of human urinary TM limited ischaemic injury, reperfusion sequelae, and systemic coagulopathy in a canine model of hepatic surgery.17
Early literature focused on TM as a placental surface protein (termed at the time fetomodulin) where it was identified as a marker of fetal endodermal differentiation essential for survival.18, 19 However, since it was recognized that embryonic lethality was independent of its anticoagulant activity3 the role of TM in tumour biology has drawn clinical interest. The key points in this genesis are presented here with a focus on future directions in cancer care.
Section snippets
The role of thrombomodulin in tumour biology
In 1987, TM was identified as a marker of invasive malignancy in vascular tumours.20 This led to further investigation that linked TM to prognosis in many tumour types including those of embryonal, epithelial and lymphatic origin.21, 22, 23, 24 Since, it is found in the placental syncytiotrophoblast of the placenta, TM was examined in chorionic diseases of the uterus and stomach.25 The finding that it is expressed in uterine choriocarcinoma but not in gastric choriocarcinoma suggests that it
Thrombomodulin and squamous cell carcinoma
Perhaps the most striking evidence for the biological role of TM in carcinogenesis is in squamous epithelium. Initially, TM was proposed to be associated with keratinocyte differentiation as it was identified in all cell layers except the basal and upper granular levels.23 Following this, TM localisation was studied in normal and dysplastic oral epithelium and it was established that TM expression is not significantly different in normal epithelium, lichen planus and mild dysplasia.26 However,
Thrombomodulin and intercellular reactions
E-cadherin is an adhesion molecule that preserves epithelial structural integrity and whose loss denotes enhanced invasive potential of cancers in many tissue types.32 In an analogous fashion, loss of TM expression is associated with a poor prognosis.33 The cell-to-cell adhesion properties of TM underpin its role in limiting metastatic behaviour independent of its anticoagulant function.10 This adhesive function is reliant on the calcium-dependent, lectin-like domain of TM that inhibits
Manipulating thrombomodulin expression in cancer
The regulation of TM is complex and vascular endothelial growth factor (VEGF), which may be tumour-derived or released following major surgery, induces endothelial TM and protein C during angiogenesis.38 Perhaps of more interest to surgeons, because of the potential to reverse negative characteristics of primary tumours and inhibit circulating cancer cell-endothelial interactions, two pharmacological substances upregulate membrane expression of TM. Pentoxifylline increases TM expression in
Conclusions
Thrombomodulin plays a key role in tumour biology and prognostics. The opportunities afforded by inducers of thrombomodulin expression provide potential therapies to improve tumour behaviour and impede transendothelial spread of cancer.
References (46)
- et al.
Protein C pathway impairment in non-symptomatic cigarette smokers
Blood Cells Mol Dis
(2002) - et al.
Elevate serum levels and reduced immunohistochemical expression of thrombomodulin in active ulcerative colitis
Gastroenterology
(1997) - et al.
Reperfusion induces sublethal endothelial injury
J Surg Res
(1998) - et al.
Fetomodulin: marker surface protein of fetal development which is modulatalble by cyclic AMP
Dev Biol
(1987) - et al.
The expression of thymidine phosphorylase and thrombomodulin in human colorectal carcinoma
Cancer Lett
(1995) - et al.
A subcloned human oesophageal cell carcinoma cell line with low thrombomodulin expression showed increased invasiveness compared with a high thrombomodulin expressing clone thromobmodulin as a possible candidate for an adhesion molecule of squamous cell carcinoma
Cancer Lett
(1998) - et al.
Expression of thrombomodulin in squamous cell carcinoma of the lung: its relationship to lymph node metastasis and prognosis of the patients
Cancer Lett
(2000) - et al.
Inhibition of invasion and experimental metastasis of murine melanoma cells by human soluble thrombomodulin
Cancer Lett
(2000) - et al.
Thrombomodulin-mediated cell adhesion: involvement of its lectin-like domain
J Biol Chem
(2003) - et al.
Thrombomoduliin dependent anticoagulant activity is regulated by vascular endothelial growth factor
Exp Cell Res
(1998)
Tumour cell adhesion to endothelial cells is increased by endotoxin via an upregulation of beta-1 integrin expression
J Surg Res
Hypertonic saline impedes tumour cell-endothelial cell interaction by reducing adhesion molecule and laminin expression
Surgery
Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C
Proc Natl Acad Sci USA
The roles of protein C and thrombomodulin in the regulation of blood coagulation
J Biol Chem
Identification of fetomodulin, a surface marker protein of fetal development, as thrombomodulin by gene cloning and functional assays
Dev Biol
Acceleration of the thrombin inactivation of single chain urokinase type plasminogen activator, by thrombomodulin
J Clin Invest
Functional thrombomodulin deficiency causes enhanced thrombus growth in a murine model of carotid artery thrombosis
Basic Res Cardiol
Thrombomodulin is present in human plasma and urine
J Clin Invest
Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells
Thromb Haemost
Endothelial dysfunction methods of assessment and application to hypertension
Curr Pharm Des
Thrombomodulin and von Willebrand factor in smokers and during smoking
Nouv Rev Fr Hematol
Interaction of endothelial cells and neutrophils in vitro. Kinetics of thrombomodulin, intercellular adhesion molecule-1 (ICAM-1), E-selectin, and vascular cell adhesion molecule-1 (VCAM-1): implications for the relevance as serological disease activity markers in vasculitides
Clin Exp Immunol
Increased levels of plasma thrombomodulin in patients with acute myocardial infarction who had thrombolytic therapy and achieved successful reperfusion
Clin Cardiol
Cited by (32)
Thrombomodulin (TM) in tumor cell differentiation and periphery blood immune microenvironment in oral squamous cell carcinoma
2018, Clinical ImmunologyCitation Excerpt :TM is a cell surface glycoprotein which is widely expressed in a variety of cell types. Apart from being an endogenous anticoagulant, TM also plays critical modulatory roles in inflammation [13], thrombosis [14], and carcinogenesis [15]. Recent evidence has revealed that TM is expressed in some cancer cells and affects cancer cell growth and metastasis [6,16–18].
Thrombomodulin reduces tumorigenic and metastatic potential of lung cancer cells by up-regulation of E-cadherin and down-regulation of N-cadherin expression
2016, Biochemical and Biophysical Research CommunicationsCitation Excerpt :Several studies discover down-regulation of TM in a variety of malignant tumors [3–5]. Noticeably, reduction of TM expression is correlated with poor prognosis of the cancer patients [8,9]. For example, decreased expression of TM is associated with tumor cell invasiveness and poor prognosis in lung cancer [10].
Regulation of thrombomodulin expression in prostate cancer cells
2012, Cancer Letters